Longitudinal analysis of blood DNA methylation identifies mechanisms of response to tumor necrosis factor inhibitor therapy in rheumatoid arthritis

Longitudinal analysis of blood DNA methylation identifies mechanisms of response to tumor necrosis factor inhibitor therapy in rheumatoid arthritis

Summary: Background: Rheumatoid arthritis (RA) is a chronic, immune-mediated inflammatory disease of the joints that has been associated with variation in the peripheral blood methylome. In this study, we aim to identify epigenetic variation that is associated with the response to tumor necrosis fa...

Full description

Bibliographic Details
Main Authors:	Antonio Julià, Antonio Gómez, María López-Lasanta, Francisco Blanco, Alba Erra, Antonio Fernández-Nebro, Antonio Juan Mas, Carolina Pérez-García, Ma Luz García Vivar, Simón Sánchez-Fernández, Mercedes Alperi-López, Raimon Sanmartí, Ana María Ortiz, Carlos Marras Fernandez-Cid, César Díaz-Torné, Estefania Moreno, Tianlu Li, Sergio H. Martínez-Mateu, Devin M. Absher, Richard M. Myers, Jesús Tornero Molina, Sara Marsal
Format:	Article
Language:	English
Published:	Elsevier 2022-06-01
Series:	EBioMedicine
Subjects:	Rheumatoid arthritis TNF inhibitors Treatment response Epigenetics DNA methylation
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352396422002341

Similar Items

Seven-chain adaptive immune receptor repertoire analysis in rheumatoid arthritis reveals novel features associated with disease and clinically relevant phenotypes
by: Adrià Aterido, et al.
Published: (2024-03-01)

Lower peripheral helper T cell levels in the synovium are associated with a better response to anti-TNF therapy in rheumatoid arthritis
by: Antonio Julià, et al.
Published: (2020-08-01)

Serial measurement of the circulating levels of tumour necrosis factor and its soluble receptors 1 and 2 for monitoring leprosy patients during multidrug treatment
by: Rosane Dias Costa, et al.
Published: (2013-12-01)

Increased serum levels of soluble tumor necrosis factor receptor-2 (sTNFR2) in patients with active toxoplasmic retinochoroiditis
by: Thais Fontes Bessa, et al.
Published: (2012-12-01)

Systemic Lupus Erythematosus: Genomics, Mechanisms, and Therapies
by: Antonio Fernández-Nebro, et al.
Published: (2012-01-01)

Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study
by: Mireia Moreno, et al.
Published: (2019-04-01)

Interleukin 1β Blockade Reduces Intestinal Inflammation in a Murine Model of Tumor Necrosis Factor–Independent Ulcerative ColitisSummary
by: Marina Liso, et al.
Published: (2022-01-01)

Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis
by: Jordi Gratacós, et al.
Published: (2019-01-01)

Early instauration granulomatous pneumonitis associated with use of etanercept in seronegative spondyloarthropathy: Case report
by: Liliana Fernández-Trujillo, et al.
Published: (2020-01-01)

Tumor necrosis factor superfamily in multiple sclerosis: from pathology to therapeutic implications
by: Federica Azzolini, et al.
Published: (2023-05-01)

Tocilizumab en artritis psoriásica ante la falla a los bloqueantes del factor de necrosis tumoral alfa
by: R. Garcia Salinas, et al.
Published: (2014-03-01)

Targeting of the CD80/86 proinflammatory axis as a therapeutic strategy to prevent severe COVID-19
by: Antonio Julià, et al.
Published: (2021-06-01)

Study of the association between the polymorphism of the TNF-α gene and prostate cancer
by: Tatiana Pardo, et al.
Published: (2019-06-01)

Tumor necrosis factor alpha of teleosts: in silico characterization and homology modeling
by: Tran Ngoc Tuan, et al.
Published: (2016-10-01)

Metformin Prevents NDEA-Induced Memory Impairments Associated with Attenuating Beta-Amyloid, Tumor Necrosis Factor-Alpha, and Interleukin-6 Levels in the Hippocampus of Rats
by: Teresa Ponce-Lopez, et al.
Published: (2023-08-01)

Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
by: Jan Marsal, et al.
Published: (2022-06-01)

TUMOR NECROSIS FACTOR-α MEMBRANE-BOUND AND SOLUBLE RECEPTORS IN NORM AND IN RHEUMATOID ARTHRITIS
by: A. A. Alshevskaya, et al.
Published: (2012-05-01)

RECOMBINANT PROTEIN OF VARIOLA VIRUS ABOLISHES THE EFFECTS OF TUMOR NECROSIS FACTOR UPON MARROW HEMATOPOIESIS IN BALB/С MICE
by: L. B. Toporkova, et al.
Published: (2014-07-01)

Anti-tumor necrosis factor-α is potentially better than tumor necrosis factor-α as the biomarker for sarcopenia: Results from the I-Lan longitudinal aging study
by: Wei-Ju Lin, et al.
Published: (2023-02-01)

The pro-inflammatory cytokine Tumor Necrosis Factor alpha (TNF-α) in Diabetic Nephropathy
by: Alia KH Mahmoud, et al.
Published: (2024-07-01)

Susceptibility to pulmonary tuberculosis: host genetic deficiency in tumor necrosis factor alpha (TNF-α) gene and tumor necrosis factor receptor 2 (TNFR2)
by: Ehsan Ghamari, et al.
Published: (2016-01-01)

Production of tumor necrosis factor-á is increased in urinary tract infections
by: Neni Susilaningsih, et al.
Published: (2012-12-01)

IMID-Biobank: Biobank of immune-mediated inflammatory diseases (IMIDs)
by: Julià A, et al.
Published: (2010-11-01)

Improvement of Function and Its Determinants in a Group of Axial Spondyloarthritis Patients Treated with TNF Inhibitors: A Real-Life Study
by: Ennio Lubrano, et al.
Published: (2020-02-01)

Estimation of the level of tumor necrosis factor-α in gingival crevicular fluid and serum in periodontal health and disease: A biochemical study
by: Kalpana Gokul
Published: (2012-01-01)

Reproductive effects of the tumor necrosis factor (TNF) deficiency in mice
by: S. O. Maslennikova, et al.
Published: (2015-12-01)

Reconciling intrinsic properties of activating TNF receptors by native ligands versus synthetic agonists
by: George Fromm, et al.
Published: (2023-09-01)

Cytokine Response to SARS-CoV-2 Infection in Children
by: Antonietta Curatola, et al.
Published: (2021-09-01)

The Role of Tumor Necrosis Factor Alpha in Adolescent Iraqi Children Infected with Toxoplasmasis
by: ashjan Mohammed, et al.
Published: (2024-01-01)

Lymphoma developing in a patient with long-term antitumor necrosis factor therapy
by: Giovana Serrão Fensterseifer, et al.
Published: (2022-07-01)

The Anti-TNF-α Therapy in the Rheumatoid Arthritis <br> A Terapia Anti-TNF-α na Artrite Reumatóide
by: Lilian Resende Faleiro, et al.
Published: (2011-06-01)

Tumor necrosis factor-α in human American tegumentary leishmaniasis
by: Alda Maria Da-Cruz, et al.
Published: (1996-04-01)

Tumour necrosis factor -308 and -238 promoter polymorphisms are predictors of a null virological response in the treatment of Brazilian hepatitis C patients
by: Tarciana Grandi, et al.
Published: (2014-06-01)

Ceramide metabolism alterations contribute to Tumor Necrosis Factor-induced melanoma dedifferentiation and predict resistance to immune checkpoint inhibitors in advanced melanoma patients
by: Carine Dufau, et al.
Published: (2024-07-01)

TNF-?, cukrzyca typu 1 i limfocyty T regulatorowe
by: Monika Ryba, et al.
Published: (2010-12-01)

Anti‐tumour necrosis factor‐α‐induced lupus in a patient receiving infliximab for sarcoidosis
by: Lachlan Stranks, et al.
Published: (2022-08-01)

Tumor necrosis factor gene polymorphism rs1800629 in patients with atherosclerotic cardiovascular diseases: A review
by: Elena V. Khazova, et al.
Published: (2023-10-01)

Tumor necrosis factor receptor‐2 signaling pathways promote survival of cancer stem‐like CD133+ cells in clear cell renal carcinoma
by: John R. Bradley, et al.
Published: (2020-02-01)

RECEPTOR SUPERFAMILY OF TUMOR NECROSIS FACTOR Α, AND HSP90 HEAT SHOCK PROTEIN: A MOLECULAR BASIS FOR INTERACTIONS
by: N. V. Ryazantseva, et al.
Published: (2014-07-01)

Editorial: Reviews and advances in inflammatory diseases and the tumor necrosis factor
by: Cristian R. Smulski
Published: (2024-04-01)